
RenovoRx (RNXT) Stock Forecast & Price Target
RenovoRx (RNXT) Analyst Ratings
Bulls say
RenovoRx is a clinical-stage biopharmaceutical company with an innovative Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which has the potential to significantly improve therapeutic outcomes for cancer patients undergoing treatment. With a rapidly growing number of active commercial cancer centers and strong commercialization efforts for its FDA-cleared proprietary medical device RenovoCath, the company has a strong potential for revenue growth in the near future. The recent appointment of a new CFO, positive Q1 results, and key milestones expected in the coming years add to the positive outlook for RenovoRx.
Bears say
RenovoRx is facing significant risks to their share price target as a result of balance sheet and liquidity concerns, as well as potential failures in clinical trials and regulatory approvals. Additionally, their financials and revenue projections paint a bleak picture for the company, with a projected net loss of $0.35 per diluted share in 2026. These challenges, combined with competition and changing macroeconomic factors, make for a negative outlook on RenovoRx's stock.
This aggregate rating is based on analysts' research of RenovoRx and is not a guaranteed prediction by Public.com or investment advice.
RenovoRx (RNXT) Analyst Forecast & Price Prediction
Start investing in RenovoRx (RNXT)
Order type
Buy in
Order amount
Est. shares
0 shares